Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
ctDNA clearance tracks with PFS in NSCLC subtype
Key clinical point: Clearance of circulating tumor DNA (ctDNA) correlates with longer progression-free survival (PFS) in patients with EGFR-mutant, MET-amplified non–small cell lung cancer (NSCLC) treated with osimertinib and savolitinib after progression on an EGFR tyrosine kinase inhibitor.
Major finding: The median PFS was 9.1 months for patients with ctDNA clearance and 3.9 months for those without ctDNA clearance (hazard ratio, 0.34; P = 0.0146).
Study details: Analysis of 144 patients from the phase 1b TATTON study, 34 of whom were evaluable for PFS.
Disclosures: The TATTON study was supported by AstraZeneca. Dr. Hartmaier is an AstraZeneca employee and shareholder.
Hartmaier R et al. AACR 2020, Abstract CT303.